We Offer Worldwide Shipping
Login Wishlist

Secoisolariciresinol Diglucoside

$87

Brand : BIOFRON
Catalogue Number : BN-B1591
Specification : 99%
CAS number : 257930-74-8
Formula : C32H46O16
Molecular Weight : 686.7
PUBCHEM ID : 72189390
Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-B1591

Analysis Method

Specification

99%

Storage

2-8°C

Molecular Weight

686.7

Appearance

Botanical Source

Structure Type

Category

SMILES

CC(C)(C)C1=CC=C(C=C1)N(C2=CC3=C(C=C2)C4=CC=CC=C4O3)C5=CC6=C(C=C5)C7=CC8=CC9=C(C=C8C(=C7S6)C#N)SC1=C9C=CC(=C1)N(C1=CC=C(C=C1)C(C)(C)C)C1=CC2=C(C=C1)C1=CC=CC=C1O2

Synonyms

7,19-bis(4-tert-butyl-N-dibenzofuran-3-ylanilino)-10,16-dithiahexacyclo[11.11.0.03,11.04,9.015,23.017,22]tetracosa-1(24),2,4(9),5,7,11,13,15(23),17(22),18,20-undecaene-12-carbonitrile

IUPAC Name

(2R,3R,4S,5S,6R)-2-[(2S,3S)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Density

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

SBVBJPHMDABKJV-NNSPVXBOSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:257930-74-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29762662

Abstract

Background
Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) have been associated with worse patient outcomes and higher costs of care than methicillin-susceptible (MSSA) infections. However, since prior studies found these differences, the healthcare landscape has changed, including widespread dissemination of community-associated strains of MRSA. We sought to provide updated estimates of the excess costs of MRSA infections.

Methods
We conducted a retrospective analysis using data from the National Inpatient Sample from the Agency for Healthcare Research and Quality for the years 2010-2014. We calculated costs for hospitalizations, including MRSA- and MSSA-related septicemia and pneumonia infections, as well as MRSA- and MSSA-related infections from conditions classified elsewhere and of an unspecified site (“other infections”). Differences in the costs of hospitalization were estimated using propensity score-adjusted mortality outcomes for 2010-2014.

Results
In 2014, estimated costs were highest for pneumonia and sepsis-related hospitalizations. Propensity score-adjusted costs were significantly higher for MSSA-related pneumonia ($40725 vs $38561; P = .045) and other hospitalizations ($15578 vs $14792; P < .001) than for MRSA-related hospitalizations. Similar patterns were observed from 2010 to 2013, although crude cost differences between MSSA- and MRSA-related pneumonia hospitalizations rose from 25.8% in 2010 to 31.0% in 2014. Compared with MSSA-related hospitalizations, MRSA-related hospitalizations had a higher adjusted mortality rate. Conclusions Although MRSA infections had been previously associated with higher hospitalization costs, our results suggest that, in recent years, costs associated with MSSA-related infections have converged with and may surpass costs of similar MRSA-related hospitalizations.

KEYWORDS

hospitalization costs, national inpatient sample, excess cost of resistant infections, propensity score-adjusted costs, antimicrobial resistance

Title

National Costs Associated With Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014

Author

Eili Y Klein,1,4,5 Wendi Jiang,5 Nestor Mojica,5 Katie K Tseng,5 Ryan McNeill,6,7 Sara E Cosgrove,2,3 and Trish M Perl8

Publish date

2019 Jan 1